echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Novartis has announced that a new drug for allergic conjunctivitis has been officially approved in China

    Novartis has announced that a new drug for allergic conjunctivitis has been officially approved in China

    • Last Update: 2021-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Pharmaceutical Mission Novartis announced today that Pataday (common name: 0.2% hydrochloric acid olotatin eye drops) has been approved by China's State Drug Administration (NMPA) for the treatment of allergic conjunctivitis-related itching.
    , according to a press release, Pataday is an upgraded version of olotta hydrochloride.
    It increased the concentration of olotatin hydrochloric acid to 0.2%, not only continue to maintain the dual-effect anti-sensitivity mechanism, but also reduce the frequency of use, once a day, can be 24 hours long-lasting and effective, for China's allergic conjunctivitis patients have brought more convenient treatment options.
    dual-acting drugs are the preferred basic drug for the treatment of allergic conjunctivitis, olotatin hydrochloric acid as a typical two-acting drug with antagonist and stable hypertrophic cell membrane, through two mechanisms can effectively suppress the symptoms and signs of patients with allergic conjunctivitis, has been recommended by China's domestic and foreign guidelines as a first-line treatment drug.
    Professor Shi Weiyun, director of The Eye Hospital of Shandong Province and head of the corneal disease group of the Ophthalmology Branch of the Chinese Medical Association, said: "0.2% hydrochloric acid olotatin eye drops are iteratively updated anaphyloatitis treatment drugs, providing a more convenient way to treat patients with allergic conjunctivitis.
    Pataday as an upgraded version of olotatad eye drops hydrochloric acid, while continuing to maintain dual-acting anti-sensitivity, will also use the frequency of reduction, is conducive to improving treatment compliance, and further standardize the management of patient self-medication.
    " allergic conjunctivitis refers to a common eye disease caused by immune disorders conjunctivitis response, in the general population of eye diseases in the rate of 6%-30%, up to 30% in children.
    its most classic performance is after the onset of the eye will be sharp itching, and even will feel the eye burning accompanied by water-like secretions, conjunctivation redness, eyelids will also swell, seriously affecting normal life.
    if the treatment is not timely, later with the progression of the disease, and even affect visual effects or cause visual impairment, so for allergic conjunctivitis, early detection, timely treatment is very important.
    , president of Novartis China, said Pataday's approval offers new and more convenient and effective treatment options for patients with allergic conjunctivitis in China.
    will work with a number of parties to make Pataday more access to Chinese patients faster.
    follow the public number of WeChat
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.